Bristol-Myers Squibb and Samsung BioLogics will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its manufacturing site in South Korea.
Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.
Samsung made headlines in 2012 when they boasted that they would be able to produce biosimilars at half the cost of what Western drugmakers would have to charge.
"It is in Samsung's DNA to produce products at low prices while meeting legal and industry requirements," Tae-Han Kim, president and CEO of Samsung BioLogics, said at the time, according to a report in FiercePharmaManufacturing.
Last year, the company completed its 69,000 sq meter plant in Songdo Incheon. It has 6 5,000-liter stainless mammalian cell culture bioreactors which can produce up to 600 kilograms of biopharmaceutical products a year.
Samsung brings biopharmaceutical capability through its fully-integrated production facilities that offer process development, drug substance manufacturing, and drug product fill & finish services at one location.
In addition to its current biologics manufacturing facility in Incheon, Korea, the company is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.